• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of diaziquone after three different dosage regimens.

作者信息

Bjornsson T D, Schold S C, Friedman H S, Schneider D, Falletta J M

出版信息

Cancer Treat Rep. 1985 Dec;69(12):1383-5.

PMID:4075314
Abstract

Diaziquone (AZQ) is a benzoquinone derivative exhibiting significant effects against CNS tumors. This study investigates the pharmacokinetics of AZQ for three different durations of continuous iv infusions, over 20 mins, 4 hrs, and 6 hrs, in nine patients with CNS malignancies. Total AZQ doses varied from 10 to 20 mg. The average elimination half-life was 37.2 +/- 13.9 mins, the total clearance was 515 +/- 280 ml/min or 11.3 +/- 5.9 ml/min/kg, and the apparent volume of distribution by area was 26.5 +/- 14.7 L or 0.62 +/- 0.50 L/kg. Peak concentrations after the 20-min infusions (three patients) varied from 0.58 to 1.20 micrograms/ml, whereas concentrations during the 4-hr infusions (three patients) varied from 0.02 to 0.37 micrograms/ml, and during the 6-hr infusions (three patients) varied from 0.02 to 0.61 micrograms/ml. These results indicate that concentrations found to exhibit minimum inhibitory effects in in vitro cell studies are achievable during prolonged iv infusions of AZQ.

摘要

相似文献

1
Pharmacokinetics of diaziquone after three different dosage regimens.
Cancer Treat Rep. 1985 Dec;69(12):1383-5.
2
The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986).
Drug Metab Dispos. 1983 Jan-Feb;11(1):41-6.
3
The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies.
J Neurosurg. 1984 May;60(5):1005-13. doi: 10.3171/jns.1984.60.5.1005.
4
Clinical pharmacology of 2,5'-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (AZQ).
Eur J Cancer Clin Oncol. 1983 May;19(5):603-6. doi: 10.1016/0277-5379(83)90175-x.
5
Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics.
Clin Pharmacol Ther. 1982 May;31(5):650-5. doi: 10.1038/clpt.1982.90.
6
The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.
J Neurooncol. 1983;1(3):219-24. doi: 10.1007/BF00165606.
7
Phase I-II diaziquone chemotherapy in brain tumors.
Cancer Treat Rep. 1984 Jun;68(6):913-4.
8
Cellular activation of diaziquone [2,5-diaziridinyl-3,6-bis (carboethoxyamino)-1,4-benzoquinone] to its free radical species.
Biochem Pharmacol. 1985 May 1;34(9):1449-55. doi: 10.1016/0006-2952(85)90683-5.
9
Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.氮丙啶基苯醌[2,5 - 二氮丙啶基 - 3,6 - 双(乙氧羰基氨基)- 1,4 - 苯醌,重氮醌,NSC 182986]在高级别胶质瘤中的II期及药代动力学研究
Cancer Res. 1983 Dec;43(12 Pt 1):6102-5.
10
Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
Cancer Res. 1982 Apr;42(4):1582-6.

引用本文的文献

1
Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.复发性恶性胶质瘤患者静脉注射卡莫司汀和安吖啶。
J Neurooncol. 1989 Sep;7(3):237-40. doi: 10.1007/BF00172916.
2
Phase I evaluation of diaziquone in childhood cancer. A Pediatric Oncology Group study.
Invest New Drugs. 1990 May;8(2):167-70. doi: 10.1007/BF00177252.
3
Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. A Pediatric Oncology Group phase II study.氮丙啶基苯醌(AZQ)治疗复发性小儿脑肿瘤及其他恶性实体瘤。一项儿科肿瘤学组的II期研究。
Invest New Drugs. 1990 Nov;8(4):401-6. doi: 10.1007/BF00198601.